Cancer incidenceCancer mortalityCancer statisticsFive-year relative survivalPopulation-based cancer registries
Figures from the paper
Abstract (AI)
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using data collected by central cancer registries (incidence, through 2022) and the National Center for Health Statistics (mortality, through 2023). In 2026, approximately 2,114,850 new cancer cases and 626,140 cancer deaths are projected to occur in the United States. The cancer mortality rate continued to decline through 2023, averting 4.8 million deaths since 1991, largely because of smoking reductions, earlier detection, and improved treatment. These interventions are also evident in rising 5-year relative survival, which reached a milestone 70% for diagnoses during 2015-2021 overall, 69% for regional-stage disease, and 35% for distant-stage (metastatic) disease, up from 63%, 54%, and 17%, respectively, in the mid-1990s. People with high-mortality cancers and advanced diagnoses had the largest gains, including increases from 32% to 62% for myeloma, 7% to 22% for liver cancer, 16% to 35% for metastatic melanoma, 8% to 18% for metastatic rectal cancer, 20% to 37% for regional lung cancer, and 2% to 10% for metastatic lung cancer. Nevertheless, lung cancer will cause more deaths in 2026 than second-ranking colorectal cancer and third-ranking pancreatic cancer combined. In summary, decades of scientific investment have translated to longer lives for people with even the most fatal cancers. However, continued progress is threatened by proposed federal cuts to cancer research and health insurance, which provides access to life-saving cancer treatment.
Key Findings
1
Approximately 2,114,850 new cancer cases and 626,140 cancer deaths are projected in the United States in 2026.
2
Despite progress, lung cancer is projected to cause more deaths in 2026 than colorectal and pancreatic cancers combined; proposed cuts to research and insurance threaten further advances.
3
Overall 5-year relative survival reached 70% for cancers diagnosed during 2015–2021, compared with 63% in the mid-1990s; regional and distant-stage survival reached 69% and 35%, respectively.
4
Survival gains were substantial for several high-mortality or advanced cancers, including myeloma, liver cancer, metastatic melanoma, metastatic rectal cancer, regional lung cancer, and metastatic lung cancer.
5
The cancer mortality rate continued declining through 2023, averting an estimated 4.8 million deaths since 1991, largely through smoking reductions, earlier detection, and improved treatment.
Research Object
Cancer occurrence, mortality, and survival in the United States
Research Subject
Recent trends, projected 2026 burden, and changes in survival outcomes across cancer types and disease stages
Publication Details
Publication Date
2026-01-01
Journal
Publisher
ISSN
Cited by
1056
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest